Selected article for: "adaptive immunity and antiviral immunity"
Author: Yatim, Nader; Boussier, Jeremy; Tetu, Pauline; Smith, Nikaïa; Bruel, Timothée; Charbit, Bruno; Barnabei, Laura; Corneau, Aurélien; Da Meda, Laetitia; Allayous, Clara; Baroudjian, Barouyr; Jebali, Majdi; Herms, Florian; Grzelak, Ludivine; Staropoli, Isabelle; Calmettes, Vincent; Hadjadj, Jerome; Peyrony, Olivier; Cassius, Charles; LeGoff, Jerome; Kramkimel, Nora; Aractingi, Selim; Fontes, Magnus; Blanc, Catherine; Rieux-Laucat, Frederic; Schwartz, Olivier; Terrier, Benjamin; Duffy, Darragh; Lebbé, Celeste
Title: Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection
  • Cord-id: 0w5gtges
  • Document date: 2021_8_18
    • ID: 0w5gtges
    Snippet: The COVID-19 pandemic has spread worldwide, yet the role of antiviral T cell immunity during infection and the contribution of immune checkpoints remain unclear. By prospectively following a cohort of 292 patients with melanoma, half of which treated with immune checkpoint inhibitors (ICIs), we identified 15 patients with acute or convalescent COVID-19 and investigated their transcriptomic, proteomic, and cellular profiles. We found that ICI treatment was not associated with severe COVID-19 and
    Document: The COVID-19 pandemic has spread worldwide, yet the role of antiviral T cell immunity during infection and the contribution of immune checkpoints remain unclear. By prospectively following a cohort of 292 patients with melanoma, half of which treated with immune checkpoint inhibitors (ICIs), we identified 15 patients with acute or convalescent COVID-19 and investigated their transcriptomic, proteomic, and cellular profiles. We found that ICI treatment was not associated with severe COVID-19 and did not alter the induction of inflammatory and type I interferon responses. In-depth phenotyping demonstrated expansion of CD8 effector memory T cells, enhanced T cell activation, and impaired plasmablast induction in ICI-treated COVID-19 patients. The evaluation of specific adaptive immunity in convalescent patients showed higher spike (S), nucleoprotein (N), and membrane (M) antigen-specific T cell responses and similar induction of spike-specific antibody responses. Our findings provide evidence that ICI during COVID-19 enhanced T cell immunity without exacerbating inflammation.

    Search related documents:
    Co phrase search for related documents
    • active disease and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • active infection absence and acute infection: 1
    • active infection and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active infection patient and acute infection: 1, 2, 3
    • active infection phase and acute infection: 1, 2
    • active infection stage and acute infection: 1
    • active patient and acute infection: 1, 2, 3, 4, 5, 6, 7
    • active phase and acute infection: 1, 2, 3, 4, 5, 6, 7, 8
    • active sars infection and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • active stage and acute infection: 1, 2, 3, 4
    • active type and acute infection: 1